Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.55 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | CTSV | O60911 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627900 | 0.77 | GAA (0.45) | POLB | |
| SCHEMBL628629 | 0.76 | CA12 (0.38) | TTK | |
| SCHEMBL627903 | 0.76 | TTK (0.59) | TTKCTSVCTSLMAOAMAOB | |
| SCHEMBL6604988 | 0.76 | TTK (0.37) | TTK | |
| SCHEMBL21267088 | 0.75 | SGMS2 (0.47) | GRM5MAOBNPC1RAB9AL3MBTL1 | |
| SCHEMBL29785180 | 0.75 | SGMS2 (0.47) | GRM5MAOBNPC1RAB9AL3MBTL1 | |
| SCHEMBL2574384 | 0.75 | TTK (0.55) | TTKCTSVCTSLMAOAMAOB | |
| SCHEMBL31052682 | 0.75 | ALPL (0.46) | — | |
| SCHEMBL10112092 | 0.75 | GSK3A (0.38) | — | |
| SCHEMBL5386440 | 0.75 | TTK (0.72) | TTKCTSVCTSLMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1820503-B1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA SRL (IT) | 2012-02-22 | — | — | EP | disclosed |
| EP-1432416-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7511136-B2 | Aminoindazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-31 | — | — | US | disclosed |
| EP-1820503-A2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | Pfizer Italia S.r.l. (IT) | 2007-08-22 | — | — | EP | disclosed |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2004-12-16 | — | — | US | disclosed |
| EP-1432416-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028720-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K15, MAP3K3, MAP3K5 | GRM5 2207/4885TTK 298/4885CTSV 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.